Revenue fell 7.55% and net profit dropped 43.01% year-over-year, mainly due to lower biopharma and vaccine sales, increased R&D, and one-time expenses. The company maintained high R&D investment and a strong cash payout ratio, but faces policy, market, and project risks.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.